Drug Usage
Conditions
Keywords
Extubation, Remifentanil, Laryngomicrosurgery
Brief summary
The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.
Detailed description
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
Interventions
DRUGRemifentanil
The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
Sponsors
Ajou University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* ASA I-II patients undergoing general anesthesia for laryngomicrosurgery
Exclusion criteria
* Anticipated difficult airway * COPD, Asthma * Recent URI (\< 2 weeks) * Severe cardiac, hepatic renal disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of cough | from end of surgery to 5 min after tracheal extubation | Number of cough or a strong and sudden contraction of the abdomen during periextubation periods |
Countries
South Korea
Outcome results
None listed